Abstract
Carcinoid tumors are part of a heterogeneous group of gastrointestinal and pancreatic endocrine tumors that are characterized by their capacity to produce and secrete hormones, 5-hydroxytryptamine, tachykinins and other mediators. These substances are thought to be responsible for the collection of symptoms, which include diarrhea, flushing and wheezing, that is known as carcinoid syndrome. Fibrosis that occurs either local to or distant from the primary tumor is one of the hallmarks of carcinoid tumors that originate from the midgut. The fibrotic process can occur in the mesentery as a desmoplastic response and may lead to obstruction of the small bowel, but it can also occur in the lungs, skin or retroperitoneum. Importantly, up to one-third of patients develop cardiac valvulopathy. One or more products that are secreted by the tumor and enter into the circulation are likely to have a role in this process. This Review discusses the incidence and prevalence of fibrosis in carcinoid syndrome and explores evidence to date for causative agents, in particular the roles of 5-hydroxytryptamine and elements of the downstream signaling pathway. Improved understanding of the etiology of carcinoid-tumor-related fibrosis may lead to better treatments for this condition than those we currently have.
Key Points
-
Fibrosis that develops either local to or distant from the primary tumor is a hallmark of carcinoid tumors that originate from the midgut
-
Fibrosis is an important clinical complication of carcinoid syndrome and is associated with ischemia and obstruction in the small bowel, and cardiac valvulopathy
-
The biology of carcinoid-syndrome-related fibrosis is not fully understood, but evidence suggests that 5-hydroxytryptamine and the 5-hydroxytryptamine 2B receptor both have a role
-
Other mediators, including TGF-β and growth factors, may also be important in the development of carcinoid-syndrome-related fibrosis
-
Improved understanding of the etiology of carcinoid-tumor-related fibrosis may lead to better treatments for this condition than those we currently have
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Modlin, I. M., Shapiro, M. D. & Kidd, M. Siegfried Oberndorfer: origins and perspectives of carcinoid tumors. Hum. Pathol. 35, 1440–1451 (2004).
Kloppel, G., Perren, A. & Heitz, P. U. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann. NY Acad. Sci. 1014, 13–27 (2004).
Modlin, I. M., Kidd, M., Latich, I., Zikusoka, M. N. & Shapiro, M. D. Current status of gastrointestinal carcinoids. Gastroenterology 128, 1717–1751 (2005).
Eriksson, B. et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumors—well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology 87, 8–19 (2008).
Modlin, I. M., Shapiro, M. D. & Kidd, M. Carcinoid tumors and fibrosis: an association with no explanation. Am. J. Gastroenterol. 99, 2466–2478 (2004).
Morgan, J. G., Marks, C. & Hearn, D. Carcinoid tumors of the gastrointestinal tract. Ann. Surg. 180, 720–727 (1974).
Kidd, M., Shapiro, M. D. & Lye, K. D. Connective tissue growth factor (CTGF) is overexpressed in ileal carcinoids. Presented at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology, January 22–24, San Francisco, California, USA (2004).
Hellman, P. et al. Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J. Surg. 26, 991–997 (2002).
Cai, Y. C. et al. Florid angiogenesis in mucosa surrounding an ileal carcinoid tumor expressing transforming growth factor-α. Am. J. Surg. Pathol. 21, 1373–1377 (1997).
Kottra, J. J. & Dunnick, N. R. Retroperitoneal fibrosis. Radiol. Clin. North Am. 34, 1259–1275 (1996).
Dev., S., al Dujaily, S. & Subbuswamy, S. G. A case of ureteric obstruction, retroperitoneal fibrosis, and carcinoid tumour. Postgrad. Med. J. 75, 38–40 (1999).
Morand, J. J. et al. Edema caused by retroperitoneal and tricuspid fibrosis with sclerodermatous cutaneous involvement disclosing carcinoid tumor. Apropos of a case and review of the literature [French]. Rev. Med. Interne. 18, 388–395 (1997).
Nelson, D. R., Stachura, M. E. & Dunlap, D. B. Ileal carcinoid tumor complicated by retroperitoneal fibrosis and a prolactinoma. Am. J. Med. Sci. 296, 129–133 (1988).
Scott, J., Foster, R. & Moore, A. Retroperitoneal fibrosis and nonmalignant ileal carcinoid. J. Urol. 138, 1435 (1987).
Gupta, A., Saibil, F., Kassim, O. & McKee, J. Retroperitoneal fibrosis caused by carcinoid tumour. Q. J. Med. 56, 367–375 (1985).
Moss, S. F. et al. Pleural involvement in the carcinoid syndrome. Q. J. Med. 86, 49–53 (1993).
Tamagno, G., Goglia, U., Villa, G. & Murialdo, G. Lung fibrosis in carcinoid syndrome. Intern. Med. 46, 425–426 (2007).
Seo, J. W., Im, J. G., Kim, Y. W., Kim, J. H. & Sheppard, M. N. Synchronous double primary lung cancers of squamous and neuroendocrine type associated with cryptogenic fibrosing alveolitis. Thorax 46, 857–858 (1991).
Miller, R. R. & Muller, N. L. Neuroendocrine cell hyperplasia and obliterative bronchiolitis in patients with peripheral carcinoid tumors. Am. J. Surg. Pathol. 19, 653–658 (1995).
Kucuk, O. et al. Lower extremity vasospasm associated with ischemic neuropathy, dermal fibrosis, and digital gangrene in a patient with carcinoid syndrome. Cancer 62, 1026–1029 (1988).
Bell, H. K., Poston, G. J., Vora, J. & Wilson, N. J. Cutaneous manifestations of the malignant carcinoid syndrome. Br. J. Dermatol. 152, 71–75 (2005).
Ratnavel, R. C., Burrows, N. P. & Pye, R. J. Scleroderma and the carcinoid syndrome. Clin. Exp. Dermatol. 19, 83–85 (1994).
Thorson, A., Biorck, G., Bjorkman, G. & Waldenstrom, J. Malignant carcinoid of the small intestine with metastases to the liver, valvular disease of the right side of the heart (pulmonary stenosis and tricuspid regurgitation without septal defects), peripheral vasomotor symptoms, bronchoconstriction, and an unusual type of cyanosis; a clinical and pathologic syndrome. Am. Heart J. 47, 795–817 (1954).
Ferrans, V. J. & Roberts, W. C. The carcinoid endocardial plaque; an ultrastructural study. Hum. Pathol. 7, 387–409 (1976).
Norheim, I. et al. Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival. Ann. Surg. 206, 115–125 (1987).
Lundin, L., Norheim, I., Landelius, J., Oberg, K. & Theodorsson-Norheim, E. Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities. Circulation 77, 264–269 (1988).
Bhattacharyya, S., Toumpanakis, C., Caplin, M. E. & Davar, J. Analysis of 150 patients with carcinoid syndrome seen in a single year at one institution in the first decade of the twenty-first century. Am. J. Cardiol. 101, 378–381 (2008).
Bhattacharyya, S., Davar, J., Dreyfus, G. & Caplin, M. E. Carcinoid heart disease. Circulation 116, 2860–2865 (2007).
Howard, R. J. et al. Carcinoid heart disease: diagnosis by two-dimensional echocardiography. Circulation 66, 1059–1065 (1982).
Zanettini, R. et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N. Engl. J. Med. 356, 39–46 (2007).
Bader, T. R., Semelka, R. C., Chiu, V. C., Armao, D. M. & Woosley, J. T. MRI of carcinoid tumors: spectrum of appearances in the gastrointestinal tract and liver. J. Magn. Reson. Imaging 14, 261–269 (2001).
Woodard, P. K., Feldman, J. M., Paine, S. S. & Baker, M. E. Midgut carcinoid tumors: CT findings and biochemical profiles. J. Comput. Assist. Tomogr. 19, 400–405 (1995).
Pantongrag-Brown, L., Buetow, P. C., Carr, N. J., Lichtenstein, J. E. & Buck, J. L. Calcification and fibrosis in mesenteric carcinoid tumor: CT findings and pathologic correlation. AJR Am. J. Roentgenol. 164, 387–391 (1995).
Horton, K. M., Lawler, L. P. & Fishman, E. K. CT findings in sclerosing mesenteritis (panniculitis): spectrum of disease. Radiographics 23, 1561–1567 (2003).
Levy, A. D., Rimola, J., Mehrotra, A. K. & Sobin, L. H. From the archives of the AFIP: benign fibrous tumors and tumorlike lesions of the mesentery: radiologic–pathologic correlation. Radiographics 26, 245–264 (2006).
Coulier, B. et al. Carcinoid tumor of the small intestine: MDCT findings with pathologic correlation. JBR-BTR 90, 507–515 (2007).
Lesurtel, M., Soll, C., Graf, R. & Clavien, P. A. Role of serotonin in the hepato-gastrointestinal tract: an old molecule for new perspectives. Cell. Mol. Life Sci. 65, 940–952 (2008).
Barnes, N. M. & Sharp, T. A review of central 5-HT receptors and their function. Neuropharmacology 38, 1083–1152 (1999).
Kim, D. Y. & Camilleri, M. Serotonin: a mediator of the brain–gut connection. Am. J. Gastroenterol. 95, 2698–2709 (2000).
Launay, J. M. et al. Ras involvement in signal transduction by the serotonin 5-HT2B receptor. J. Biol. Chem. 271, 3141–3147 (1996).
Nebigil, C. G., Launay, J. M., Hickel, P., Tournois, C. & Maroteaux, L. 5-hydroxytryptamine 2B receptor regulates cell-cycle progression: crosstalk with tyrosine kinase pathways. Proc. Natl Acad. Sci. USA 97, 2591–2596 (2000).
Mason, J. W., Billingham, M. E. & Friedman, J. P. Methysergide-induced heart disease: a case of multivalvular and myocardial fibrosis. Circulation 56, 889–890 (1977).
Connolly, H. et al. Valvular heart disease associated with fenfluramine–phentermine. N. Engl. J. Med. 337, 581–588 (1997).
Antonini, A. & Poewe, W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol. 6, 826–829 (2007).
Jagroop, I. A. & Mikhailidis, D. P. An investigation of the serotonergic effects of fenfluramine, dexfenfluramine and dexnorfenfluramine using platelets as neuronal models. Platelets 11, 161–165 (2000).
Gustafsson, B. I. et al. Long-term serotonin administration induces heart valve disease in rats. Circulation 111, 1517–1522 (2005).
Mekontso-Dessap, A. et al. Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice. Circulation 113, 81–89 (2006).
Musunuru, S., Carpenter, J. E., Sippel, R. S., Kunnimalaiyaan, M. & Chen, H. A mouse model of carcinoid syndrome and heart disease. J. Surg. Res. 126, 102–105 (2005).
Wang, B. et al. Regulation of collagen synthesis by inhibitory Smad7 in cardiac myofibroblasts. Am. J. Physiol. Heart Circ. Physiol. 293, H1282–H1290 (2007).
Ruddell, R. G. et al. A role for serotonin (5-HT) in hepatic stellate cell function and liver fibrosis. Am. J. Pathol. 169, 861–876 (2006).
Caplin, M. E. et al. Carcinoid tumour. Lancet 352, 799–805 (1998).
Kulke, M. H. & Mayer, R. J. Carcinoid tumors. N. Engl. J. Med. 340, 858–868 (1999).
Jian, B. et al. Serotonin mechanisms in heart valve disease I: serotonin-induced upregulation of transforming growth factor-beta1 via G-protein signal transduction in aortic valve interstitial cells. Am. J. Pathol. 161, 2111–2121 (2002).
Moller, J. E. et al. Factors associated with progression of carcinoid heart disease. N. Engl. J. Med. 348, 1005–1015 (2003).
Nilsson, C. L., Brodin, E. & Ekman, R. Substance P and related peptides in porcine cortex: whole tissue and nuclear localization. J. Chromatogr. A 800, 21–27 (1998).
Chaudhry, A., Funa, K. & Oberg, K. Expression of growth factor peptides and their receptors in neuroendocrine tumors of the digestive system. Acta Oncol. 32, 107–114 (1993).
Waltenberger, J. et al. Involvement of transforming growth factor-beta in the formation of fibrotic lesions in carcinoid heart disease. Am. J. Pathol. 142, 71–78 (1993).
Kidd, M. et al. CTGF, intestinal stellate cells and carcinoid fibrogenesis. World J. Gastroenterol. 13, 5208–5216 (2007).
Lal, A. & Chen, H. Treatment of advanced carcinoid tumors. Curr. Opin. Oncol. 18, 9–15 (2006).
Bhattacharyya, S., Toumpanakis, C., Caplin, M. E. & Davar, J. Usefulness of N-terminal pro-brain natriuretic peptide as a biomarker of the presence of carcinoid heart disease. Am. J. Cardiol. 102, 938–942 (2008).
Ohrvall, U. et al. Method for dissection of mesenteric metastases in midgut carcinoid tumors. World J. Surg. 24, 1402–1408 (2000).
Howell, S. B. et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann. Intern. Med. 97, 845–851 (1982).
Moertel, C. G., Kvols, L. K. & Rubin, J. A study of cyproheptadine in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer 67, 33–36 (1991).
Robertson, J. I. Carcinoid syndrome and serotonin: therapeutic effects of ketanserin. Cardiovasc. Drugs Ther. 4 (Suppl. 1), S53–S58 (1990).
Noppen, M., Jacobs, A., Van Belle, S., Herregodts, P. & Somers, G. Inhibitory effects of ranitidine on flushing and serum serotonin concentrations in carcinoid syndrome. Br. Med. J. (Clin. Res. Ed.) 296, 682–683 (1988).
Wymenga, A. N., de Vries, E. G., Leijsma, M. K., Kema, I. P. & Kleibeuker, J. H. Effects of ondansetron on gastrointestinal symptoms in carcinoid syndrome. Eur. J. Cancer 34, 1293–1294 (1998).
Jacobsen, M. B. Ondansetron in carcinoid syndrome. Lancet 340, 185 (1992).
Hauso, O. et al. Long-term serotonin effects in the rat are prevented by terguride. Regul. Pept. 143, 39–46 (2007).
Ciccarelli, E., Touzel, R., Besser, M. & Grossman, A. Terguride—a new dopamine agonist drug: a comparison of its neuroendocrine and side effect profile with bromocriptine. Fertil. Steril. 49, 589–594 (1988).
Greenblatt, D. Y. et al. Valproic acid activates Notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells. Oncologist 12, 942–951 (2007).
Kunnimalaiyaan, M. & Chen, H. The Raf-1 pathway: a molecular target for treatment of select neuroendocrine tumors? Anticancer Drugs 17, 139–142 (2006).
Brown, P., Pappas, C., Frazier, K., Turnage, A. & Liu, Q. LX1032: A novel approach for managing gastrointestinal symptoms in carcinoid syndrome. [Abstract C16] Presented at the 6th Annual Conference of the European Neuroendocrine Tumor Society: 2009 March 5–7, Granada, Spain.
Acknowledgements
Charles P. Vega, University of California, Irvine, CA, is the author of and is solely responsible for the content of the learning objectives, questions and answers of the Medscape-accredited continuing medical education activity associated with this article.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Druce, M., Rockall, A. & Grossman, A. Fibrosis and carcinoid syndrome: from causation to future therapy. Nat Rev Endocrinol 5, 276–283 (2009). https://doi.org/10.1038/nrendo.2009.51
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2009.51
This article is cited by
-
What Causes Desmoplastic Reaction in Small Intestinal Neuroendocrine Neoplasms?
Current Oncology Reports (2022)
-
Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome
Journal of Patient-Reported Outcomes (2019)
-
Carcinoid Syndrome: Updates and Review of Current Therapy
Current Treatment Options in Oncology (2019)
-
Echocardiography in functional midgut neuroendocrine tumors: When and how often
Reviews in Endocrine and Metabolic Disorders (2017)
-
Stenting of the Superior Mesenteric Vein in Midgut Carcinoid Disease with Large Mesenteric Masses
World Journal of Surgery (2010)